Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III master protocol of BNT327 (pumitamig) plus chemotherapy in first-line NSCLC
jRCT2051250042Phase 3Recruiting
- Sponsor
- BioNTech SE
- Start
- Nov 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of pumitamig in non-small cell lung cancer (NSCLC) (8 arms), sponsored by BioNTech SE. Started Nov 2025; status: recruiting.
02
Drugs
pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051250042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250042.